Faculty of Medicine, University of Sao Paulo, Av. Dr. Arnaldo, 455, Sao Paulo, SP, 01246-903, Brazil.
Laboratório de Endocrinologia Celular e Molecular LIM 25 e Unidade de Doencas Osteometabolicas, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Arnaldo, 455 sala 4344, Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil.
Osteoporos Int. 2020 May;31(5):905-912. doi: 10.1007/s00198-019-05268-0. Epub 2020 Jan 2.
The congenital adrenal hyperplasia population seems to have an intrinsic tendency to a high frequency of low bone mass. However in this single-center and long-term evaluated cohort, the simplified corticoid regimen, with exclusive dexamethasone single dose reposition during adulthood, did not represent a risk factor for decrease in bone health.
The impact of long-term and supposedly physiological doses of gluco and mineralocorticoid (GC/MC) on bone mineral density (BMD) in congenital adrenal hyperplasia (CAH) remains discordant among studies, which contain different clinical forms and corticoid regimens. Our aim was to evaluate the BMD in CAH adults receiving similar GC regimen since childhood and to correlate it with GC/MC cumulative doses.
Only patients with good compliance, who used cortisone acetate (CA) during childhood and dexamethasone after the final height achievement. Cumulative GC/MC doses were calculated from diagnosis until last evaluation. BMD was analyzed by the first and last energy X-ray absorptiometry (DXA) scans performed.
Twenty simple virilizing (SV) and 14 salt wasting (WS) whose mean age was 26 ± 6 years, mean CA, dexamethasone, and fludrocortisone cumulative doses were 63,813 ± 32,767, 812 ± 558, and 319 ± 325 mg/m, respectively. Based on the last DXA, low BMD was observed in 11% of patients, total hip Z-score was lower in the SW than SV form (p = 0.04). Cumulative CA dose had an inverse correlation with femoral neck Z-score (p < 0.01). Total cumulative GC and MC doses had an inverse correlation with total hip Z-score (p < 0.01). In the analysis of sequential BMD during dexamethasone therapy, no association was observed among cumulative GC/MC doses, clinical forms, sex, and lumbar Z-score delta.
Even though a low CA regimen during growth periods in addition to MC replacement appears to have an influence on BMD at femoral sites, interestingly a low dexamethasone one does not seem to be deleterious for bone health in adulthood.
先天性肾上腺皮质增生症(CAH)人群似乎存在骨量低频率高的固有趋势。然而,在这项单中心和长期评估的队列研究中,简化的皮质激素方案,即成年期仅单次给予地塞米松,并不代表骨质健康下降的危险因素。
评估长期应用糖皮质激素(GC)/盐皮质激素(MC)对 CAH 患者骨密度(BMD)的影响,既往研究中包含不同的临床类型和皮质激素方案,结果并不一致。本研究旨在评估接受类似 GC 方案治疗的 CAH 成年患者的 BMD,并与 GC/MC 累积剂量相关。
仅纳入依从性良好的患者,这些患者在儿童期使用醋酸可的松(CA),在达到最终身高后使用地塞米松。从诊断到最后一次评估,计算 GC/MC 累积剂量。分析首次和最后一次能量 X 射线吸收法(DXA)扫描的 BMD。
20 例单纯男性化型(SV)和 14 例失盐型(WS)患者的平均年龄为 26±6 岁,CA、地塞米松和氟氢可的松的累积剂量分别为 63813±32767、812±558 和 319±325mg/m。根据最后一次 DXA,11%的患者存在低骨密度,WS 型的全髋关节 Z 评分低于 SV 型(p=0.04)。CA 累积剂量与股骨颈 Z 评分呈负相关(p<0.01)。总 GC 和 MC 累积剂量与全髋关节 Z 评分呈负相关(p<0.01)。在分析地塞米松治疗期间的连续 BMD 时,未观察到累积 GC/MC 剂量、临床类型、性别和腰椎 Z 评分变化之间存在关联。
尽管生长期间应用低剂量 CA 方案联合 MC 替代治疗似乎对股骨部位的 BMD 有影响,但有趣的是,低剂量地塞米松在成年期对骨骼健康似乎没有不良影响。